This phase III trial is trying to determine whether the combination of two immunotherapy drugs (nivolumab and ipilimumab) is effective in preventing cancer recurrence in patients with renal cell carcinoma, who have had part or all of their kidney removed.
This trial is treating patients with Renal Cell Carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had a certain type of treatment or surgical procedure.
- Your cancer has not spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Bristol-Myers Squibb (BMS)
The purpose of this study is to determine whether the combination of nivolumab and ipilimumab is safe and effective for delaying or preventing recurrence of cancer in patients who have experienced the partial or entire removal of a kidney. There will be an experimental and placebo arm.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More